In reply-Strategies of Screening for Fabry Disease in Patients With Unexplained Left Ventricular Hypertrophy

Mayo Clin Proc. 2019 Aug;94(8):1646. doi: 10.1016/j.mayocp.2019.05.004.

Authors

Darrell B Newman¹, Michael J Ackerman²

Affiliations

¹ Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN.
² Division of Pediatric Cardiology, Department of Pediatrics, Department of Cardiovascular Disease and Department of Molecular Pharmacology and Experimental Therapeutics, Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic, Rochester, MN.

PMID: 31378242
DOI: 10.1016/j.mayocp.2019.05.004

No abstract available

Publication types

Letter
Comment

MeSH terms

Cost-Benefit Analysis
Fabry Disease*
Humans
Hypertrophy, Left Ventricular
alpha-Galactosidase*

Substances

alpha-Galactosidase